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Abstract
Background—Pulmonary disease among infants of <28 weeks' gestation (extremely low
gestational age newborns) often has the following pattern: the infant starts out with little need for
supplemental oxygen and ventilatory support in the first postnatal week but then has pulmonary
deterioration in the second postnatal week, with an increased need for supplemental oxygen and
respiratory support. We evaluated the antecedents and correlates of patterns of early lung disease,
with particular emphasis on pulmonary deterioration, in a large cohort study (the Extremely Low
Gestational Age Newborn [ELGAN] study).
Patients and Methods—We examined data collected prospectively on 1340 infants born between
2002 and 2004 at 23 to 27 completed weeks of gestation and who survived to 14 days. Pulmonary
deterioration was defined as receipt of fraction of inspired oxygen <0.23 on any day between days
3 and 7 and receipt of fraction of inspired oxygen ≥ 0.25 on day 14.
Results—One fifth (20%) of the infants had consistently low fraction of inspired oxygen,
approximately two fifths (38%) had pulmonary deterioration, and the remaining approximately two
fifths (43%) had consistently high fraction of inspired oxygen (early and persistent lung dysfunction).
Compared with infants who had consistently low fraction of inspired oxygen, infants who
experienced pulmonary deterioration had lower gestational ages and lower birth weights, had higher
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What's Known on This Subject
ELGANs experience different patterns of respiratory disease in the first 2 postnatal weeks.
What This Study Adds
We examined the antecedents and modifiers of 3 a priori–defined patterns of respiratory disease in ELGANs.
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scores for neonatal acute physiology, and received more intensive modes of respiratory support.
Gender, multifetal pregnancy, cesarean delivery, antenatal steroids, chorioamnionitis, and funisitis
were not associated with pulmonary deterioration. The incidence of chronic lung disease, defined as
oxygen therapy at 36 weeks' postmenstrual age, was 17% in the consistently low fraction of inspired
oxygen group, 51% in the pulmonary deterioration group, and 67% in the early and persistent
pulmonary dysfunction group. The incidence of death in these 3 groups before 36 weeks'
postmenstrual age was 1%, 3%, and 5%, respectively.
Conclusions—Nearly 40% of extremely low gestational age newborns experience pulmonary
deterioration in the first 2 postnatal weeks, and half of these infants develop chronic lung disease.
Indicators of developmental immaturity and illness severity were associated with both pulmonary
deterioration and chronic lung disease. Studying the antecedents of pulmonary deterioration might
provide new insights about chronic lung disease pathogenesis.
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Nearly all infants born before 28 weeks' gestation (extremely low gestational age newborns
[ELGANs]) require ventilatory assistance immediately after birth; most often with mechanical
ventilation and supplemental oxygen.1 During the first 2 postnatal weeks, several distinct
patterns of lung disease emerge.2–6 Some ELGANs have relatively little lung disease and
rapidly recover, whereas others have early and persistent pulmonary dysfunction (EPPD)
characterized by the need for mechanical ventilation and high concentrations of supplemental
oxygen during the weeks after birth. A third group has resolution of their initial lung disease
during the first week when mechanical ventilation may no longer be necessary and the need
for oxygen is markedly reduced, only to deteriorate during the second week resulting in the
need for increased supplemental oxygen and resumption of mechanical ventilation. We
describe this group as having pulmonary deterioration (PD).
Rarely do infants with PD die; however, approximately one half develop chronic lung disease
(CLD), also known as bronchopulmonary dysplasia.7 Therefore, PD seems to be an important
early identifier of infants likely to develop CLD. The antecedents of PD have not yet been
identified, although late surfactant deficiency might be a contributing factor.8 Bacteremia,
pneumonia, and patent ductus arteriosus (PDA) are sometimes suspected as the cause of PD,
but most often no cause is identified. Because PD is associated with CLD, acquiring a better
understanding of PD might provide important insights about CLD.
A major advantage to focusing on PD, rather than the more established outcome, CLD, is that
PD can be identified early in life. The events that may confound our understanding of PD are
fewer in number than those that occur between birth and the diagnosis of CLD at 36 weeks'
postmenstrual age. Finally, it is possible that risk factors for PD might be modified or mitigated,
and that reducing exposure to these risk factors might reduce the likelihood of CLD. Therefore,
we sought to identify the antecedents and modifiers of 3 patterns of early lung disease, with
particular emphasis on PD, in a large cohort of ELGANs.
Methods
The study population included infants enrolled in a multicenter epidemiologic study to identify
characteristics and exposures that increase the risk of structural and functional neurologic
disorders in ELGANs (the ELGAN Study).9 From March 2002 to August 2004, women
delivering before the 28th week of gestation at 1 of 14 participating institutions were asked to
enroll in the study. Individual institutional review boards approved the enrollment and consent
processes. Of 1506 infants enrolled, 1340 survived the first 2 postnatal weeks and were thus
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eligible for the analyses presented here. Historical, demographic, and clinical data were
abstracted from maternal and infant charts, and histologic and microbiologic studies of the
placentas were performed to identify evidence of inflammation and infection.
ELGANs were classified into 3 mutually exclusive groups: those with consistently low fraction
of inspired oxygen (FIO2) (an FIO2 consistently <0.23 on all days between 3 and 7 postnatal days
and receiving FIO2 ≤ 0.25 on day 14), those with PD (an FIO2 < 0.23 on any days between 3 and
7 days and receiving FIO2 > 0.25 on day 14), and those with EPPD (an FIO2 consistently ≥ 0.23
on all days between 3 and 7 postnatal days and receiving FIO2 > 0.25 on day 14). For individual
infants, the FIO2 assigned for each day of life was the mode FIO2 for that day. Day 0 began at
the time of birth and continued through 24 hours of age. Day 1 began at the end of the first 24
hours of age and ended at midnight of that calendar day. Thus, day 1 varies in length. After
day 1, all days began and ended at midnight.
We examined candidate risk factors for each respiratory outcome defined above including
gender, gestational age, birth weight z score (based on an external standard10), maternal race,
receipt of antenatal steroids, chorioamnionitis, funisitis, pregnancy complications, and
multifetal pregnancy. Gestational age was determined by an a priori hierarchy based in order
of decreasing preference on: fetal ultrasound before 14 weeks (62%), ultrasound between 14
and 18 weeks (17%), ultrasound after 18 weeks with a consonant maternal report of the
beginning of the last menstrual cycle (13%), maternal report of the beginning of the last
menstrual cycle only (7%), and gestational age recorded in the log of the NICU (1%).
The presence of chorioamnionitis (defined by polymorphonuclear leukocytes in the chorion or
chorioamnion) and funisitis (defined by polymorphonuclear leukocytes in the wall of a blood
vessel in the umbilical cord or the chorionic plate) was determined by a pathologist at each
institution who first engaged in training procedures to minimize interobserver variability, was
masked to maternal history, and used predefined operational definitions.10,11
To further identify evidence of infection, we cultured chorion/decidua biopsies of the placenta.
Immediately after delivery, the chorioamnionic membranes were removed from an area on the
fetal surface of the placenta. Specimens of placenta were then collected under sterile conditions,
flash-frozen, stored locally −80°C, and later shipped to a central laboratory where they were
processed in a standardized manner.12,13
We examined bacteriologic information from the infant-placenta dyads according to mode of
delivery, first, considering all deliveries, and second, limiting analyses to infants born by
cesarean section. The latter approach has the disadvantage that it excludes a moderate number
of deliveries initiated by factors associated with intrauterine infection (eg, preterm labor and
rupture of membranes). On the other hand, it has the advantage of excluding placentas
contaminated during passage through the vagina.
We examined the occurrence during the first 2 postnatal weeks of the following factors: Score
for Neonatal Acute Physiology II (SNAP-II),14 mode of ventilation, diagnosis and treatment
of PDA, diagnosis of bacteremia, and medication use. Mode of ventilation was defined as the
highest level of support on each day and ranged from no support, supplemental oxygen by hood
or nasal cannula, nasal continuous positive airway pressure, and conventional mechanical
ventilation to high frequency ventilation. We did not record the devices used. Presumed
bacteremia was defined as an episode of suspected bacteremia during which the infants were
treated with antibiotics for more than 72 hours, but the blood culture was negative. Confirmed
bacteremia required a positive blood culture. The diagnosis of PDA was assigned by clinicians
without uniformity of definition; echocardiographic confirmation was not required. CLD was
defined as oxygen therapy at 36 weeks' adjusted gestation. Medications were recorded if given
on any day during the first week and included surfactant, analgesics (ie, morphine, fentanyl,
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or methadone), sedatives (ie, lorazepam, midazolam, or chloral hydrate), vitamin A, and
steroids (ie, hydrocortisone and dexamethasone). We did not collect data about the dosages.
Infants in the EPPD and PD groups were compared in univariate analyses to those in the low
FIO2 group to identify the characteristics that distinguished them. Characteristics that
distinguished infants who developed PD from infants who remained in the low FIO2 group with
a P value of ≤ .30 were then included in logistic regression analyses to assess the strength of
association of each characteristic/exposure to the risk of PD, adjusted for other factors included
in the regression. We also created separate logistic regression models of the risk of EPPD based
on characteristics and exposures that distinguished children who developed EPPD from infants
who remained in the low FIO2 group.
Gestational age and birth weight z score15,16 were included in every multivariable model.
Multivariate logistic regression models were developed using manual backward selection,
dropping the least significant variable followed by rerunning the model with the remaining
variables. A model was complete when all of the variables that remained were associated with
the outcome at a level of P < .1. The dropped variables were individually reintroduced to see
if they now contributed to the complete model.
Results
The cohort comprised 1340 infants: 249 (20%) infants had consistently low FIO2, 484 (38%)
infants had PD, and 576 (43%) infants had EPPD (Fig 1).
Univariate Analysis
Compared with the consistently low FIO2 group, infants in the PD group tended to have a lower
gestational age, lower birth weight, and a higher SNAP-II (Table 1). Compared with the EPPD
group, infants in the PD group had a higher gestational age, higher birth weight, and a lower
SNAP-II. Gender, multifetal pregnancy, antenatal steroids, initiator of delivery, cesarean
delivery, and histologic indicators of inflammation did not distinguish one group from another.
In samples from the entire cohort and from those delivered by cesarean section, no one
organism was identified as having a statistically significant association with pulmonary
outcomes. Mycoplasma species were recovered most frequently from the placentas of infants
in the EPPD group, and least frequently from the placentas of infants in the consistently low
FIO2 group (Table 2). No other species showed this gradient. Compared with infants whose
placenta did not harbor a vaginal organism, infants whose placenta did harbor a vaginal
organism were at modestly greater risk of PD (45% vs 36%).
With increasingly severe and persistent respiratory dysfunction (from the low FIO2 group, to
the PD group, to the EPPD group), the frequency of undesirable characteristics/exposures
increased, including high SNAP-IIs, presumed bacteremia, confirmed bacteremia,
echocardiogram-documented PDA, medical and surgical treatment of PDA, and high
frequency ventilation on days 0 and 7 (Table 3). The frequency of receipt of the following
medications also increased: surfactant, hydrocortisone, analgesics, sedatives, and vitamin A
(Table 3).
In addition, the incidence of CLD was 17% (41/243) among children in the low FIO2 group,
51% (238/469) among children in the PD group, and 67% (358/535) among children in the
EPPD group. Among all infants with CLD, 37% had an antecedent history of PD. On day 0
through day 7, the frequency of mechanical ventilation was lowest in the low FIO2 group, and
highest in the EPPD group (Fig 2).
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In multivariate analysis comparing the PD group to the low FIO2 group, low gestational age,
low birth weight z score, and mode of ventilation on postnatal day 7 were associated with
increase risk of PD (Table 4). The increased risk associated with a diagnosis of PDA
approached, but did not reach, nominal statistical significance (P = .07).
When comparing the EPPD group to the low FIO2 group, low gestational age, low birth weight
z score, mechanical ventilation on day 7, confirmed bacteremia, receipt of vitamin A and
surfactant, and treatment of PDA were associated with increased risk of EPPD (Table 5). The
P value associated with a diagnosis of PDA nearly achieved nominal statistical significance
(P = .06). Histologic chorioamnionitis and funisitis were not associated with PD or EPPD in
these models (data not presented).
Discussion
The importance of EPPD and PD is that infants who have these respiratory patterns are at very
high risk of CLD. Early descriptions of CLD noted its association with severe early lung disease
that would be categorized as EPPD in our study. More recently, an additional pattern of early
disease preceding CLD has been reported. Among infants who developed CLD, Charafeddine
et al2 observed 2 groups of infants who did not have antecedent EPPD. Infants in these groups
were either well throughout the first week of life or had recovered from their acute lung disease
by the end of the first postnatal week, but then developed an oxygen requirement during the
second postnatal week. The authors were the first to describe this experience as “atypical
CLD.”2 These infants experienced what we call PD.
Streubel et al6 identified a group of infants who had an FIO2 of <0.25 for 3 days after recovery
from respiratory distress syndrome (RDS) and a subsequent increase in FIO2 to at least 40%;
these infants were classified as having atypical CLD. All infants in this atypical CLD group
developed bronchopulmonary dysplasia (BPD). Compared with infants with no BPD, infants
with atypical CLD were smaller, less mature, and had a higher rate of sepsis and pneumothorax.
In a similar study, Panickar et al3 reported that ∼40% of all who developed BPD had an
antecedent history of PD. We confirmed this relationship, finding that >50% of children with
EPPD or PD developed CLD compared with <20% of children in the low FIO2 group.
The terms in current use in the literature are confusing. We feel that our terms (PD and EPPD)
describe a clinical pattern of respiratory disease, defined by FIO2, which may or may not develop
into CLD. Previous authors identified patients as having CLD (usually at 36 weeks' adjusted
gestation), and then looked retrospectively to identify the pattern of lung disease (eg, “atypical
RDS”2). We do not believe that infants with PD or EPPD necessarily have RDS. The advantage
of using our terms is threefold: first, we, and other investigators, will be able to relate events
that occur after the pattern of lung disease to these patterns (eg, CLD and, in future studies,
neurodevelopmental outcomes); second, a clinician is now able to distinguish these patterns
by the 14th postnatal day and place infants into appropriate risk categories of morbidities
associated with prematurity (namely, CLD); and third, therapeutic modalities designed to
reduce the incidence of morbidities associated with prematurity (eg, CLD) can use these
patterns as markers of risk.
In our cohort of ELGANs, PD occurred in 38% of infants, a prevalence similar to that of EPPD
(43%). Only 19% of ELGANs were in the consistently low FIO2 group, having little or no
evidence of lung dysfunction throughout the first 2 postnatal weeks. We found that infants with
PD had a risk factor profile that was intermediate between that of infants with consistently low
FIO2 and infants with EPPD. This risk factor profile included birth weight, gestational age, and
a variety of treatments and complications that are associated with low gestational age, such as
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higher SNAP-II values, treatment with mechanical ventilation, patent ductus arteriosus,
treatment with hydrocortisone, and confirmed bacteremia.
To our knowledge, the entity of PD is unique to ELGANs. The peculiar predisposition of
ELGANs to PD could be explained on the basis of processes that are developmentally regulated
resulting in vulnerability by virtue of birth at extreme prematurity (eg, adrenal glucocorticoid
synthesis and antioxidant production).17–19 This possibility is supported by our observation
of the association between PD and early gestational age.
ELGANs may also be vulnerable because of a unique environmental exposure that is distinct
to this population. One possibility is an intrauterine exposure. The most common feature that
distinguishes the intrauterine environment of ELGANs from more mature neonates is the far
greater likelihood of intrauterine infection.20 Although not a consistent finding, intrauterine
infection has been associated with the development of CLD, either as a risk factor by itself21
or when antenatal infection is associated with the need for prolonged mechanical ventilation.
22
Neither EPPD nor PD had an increased frequency of histologic expressions of inflammation
in the placenta as chorioamnionitis and funisitis. Therefore, we explored the possibility that
placental infection with a specific organism might be associated with risk for PD. In previous
work, postnatal recovery of Ureaplasma urealyticum from tracheal samples has been
associated with the development of CLD.23 Although not statistically significant, among our
study subjects Mycoplasma species, including Ureaplasma, was detected more frequently
among the placentas of infants who developed EPPD.
Besides gestational age and birth weight, the most consistent risk factor for PD was treatment
with mechanical ventilation (conventional or high-frequency ventilation) on postnatal day 7.
It is not clear whether this association reflects a causal link between ventilation mode and PD
or whether ventilation mode identifies infants with more severe lung disease. Treatment with
oxygen during the first week of life in the low FIO2 and PD groups was similar, as was the
frequency of the diagnosis of apnea at any time during the study period.
Two neonatal events, confirmed bacteremia and persistent PDA, have been associated with
adverse outcomes, including CLD.24 However, prophylactic treatment of the PDA has not been
demonstrated to reduce the risk of CLD.25 We examined both of these antecedents in relation
to patterns of early lung disease. Bacteremia was a risk factor for EPPD but not for PD. This
finding suggests that the etiology of persistent, severe lung disease may be different from the
etiology of PD. The relationship between EPPD and both intrauterine exposure to specific
organisms and postnatal infection implicates an infectious/inflammatory exposure in the
pathogenesis.21
The diagnosis of PDA at any time during the first 2 weeks of life may be a risk factor for both
EPPD and PD as this association approached statistical significance for both entities. A cause-
and-effect relationship between shunting through a PDA and lung disease has biological
plausibility.15,16 It is possible that our finding an association between PDA and both EPPD
and PD is explained on the basis of an acquisition bias, in that infants with more severe lung
disease were more likely to be clinically suspected of having a PDA and to be subjected to
diagnostic testing (ie, echocardiography). Alternatively, PDA may be causally related to PD.
Our data about indomethacin and/or ligation for PDA do not allow us to assess if these therapies
reduced the risks of EPPD or PD. Determining the contribution of the PDA is important,
because it may be a modifiable risk factor.
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We examined the patterns of lung dysfunction in the first 2 weeks of life and the risk factors
associated with these patterns in a large cohort of ELGANs. Infants with PD and EPPD tended
to have lower gestational ages and lower birth weights than infants with consistently low
FIO2. The only statistically significant potentially modifiable risk factor unique to infants in the
PD group was receipt of mechanical ventilation (conventional or high-frequency ventilation)
on postnatal day 7, although PDA might also be important. Future studies that characterize the
inflammatory milieu of the lung by measuring biomarkers in tracheal fluid may suggest
pathologic mechanisms for PD and strategies for prevention. Additional studies are also needed
to characterize the relationship between these early patterns of lung dysfunction and subsequent
health and development during infancy.
Acknowledgments
This study was supported by a cooperative agreement with National Institute of Neurological Disorders and Stroke
grant 5U01NS040069-04. Dr Bose was supported by the Thrasher Research Fund.
We acknowledge our ELGAN Study colleagues: Olaf Dammann (Tufts Medical Center, Boston, MA), Bhavesh L.
Shah (Baystate Medical Center, Springfield, MA), Camilia Martin (Beth Israel Deaconess Medical Center, Boston,
MA), Robert Insoft (Brigham and Women's Hospital, Boston, MA), Karl Kuban (Boston Medical Center, Boston,
MA), Francis Bednarek (UMass Memorial Health Center, Worcester, MA), John Fiascone (Tufts Medical Center,
Boston, MA), Richard Ehrenkranz (Yale-New Haven Children's Hospital, New Haven, CT), T. Michael O'Shea (Wake
Forest University/Baptist Medical Center, Winston-Salem, NC), Stephen C. Engelke (University Health Systems of
Eastern Carolina, Greenville, NC), Carl Bose (University of North Carolina, Chapel Hill, NC), Mariel Poortenga and
Ed Beaumont (DeVos Children's Hospital, Grand Rapids, MI), Nigel Paneth (Sparrow Hospital, Lansing, MI), Michael
D. Schreiber (University of Chicago Hospital, Chicago, IL), Daniel Batton (William Beaumont Hospital, Royal Oak,
MI), Greg Pavlov (Frontier Science and Technology Research Foundation, Amherst, NY), and Deborah Hirtz, our
project officer.
References
1. Finer NN, Carlo WA, Duara S, et al. Delivery room continuous positive airway pressure/positive end-
expiratory pressure in extremely low birth weight infants: a feasibility trial. Pediatrics 2004;114(3):
651–657. [PubMed: 15342835]
2. Charafeddine L, D'Angio CT, Phelps DL. Atypical chronic lung disease patterns in neonates. Pediatrics
1999;103(4 pt 1):759–765. [PubMed: 10103299]
3. Panickar J, Scholefield H, Kumar Y, Pilling DW, Subhedar NV. Atypical chronic lung disease in
preterm infants. J Perinat Med 2004;32(2):162–167. [PubMed: 15085893]
4. Choi CW, Kim BI, Koh YY, Choi JH, Choi JY. Clinical characteristics of chronic lung disease without
preceding respiratory distress syndrome in preterm infants. Pediatr Int 2005;47(1):72–79. [PubMed:
15693871]
5. Choi CW, Kim BI, Park JD, Koh YY, Choi JH, Choi JY. Risk factors for the different types of chronic
lung diseases of prematurity according to the preceding respiratory distress syndrome. Pediatr Int
2005;47(4):417–423. [PubMed: 16091080]
6. Streubel AH, Donohue PK, Aucott SW. The epidemiology of atypical chronic lung disease in extremely
low birth weight infants. J Perinatol 2008;28(2):141–148. [PubMed: 18059466]
7. Kobaly K, Schluchter M, Minich N, et al. Outcomes of extremely low birth weight (<1 kg) and
extremely low gestational age (<28 weeks) infants with bronchopulmonary dysplasia: effects of
practice changes in 2000 to 2003. Pediatrics 2008;121(1):73–81. [PubMed: 18166559]
8. Merrill JD, Ballard RA, Cnaan A, et al. Dysfunction of pulmonary surfactant in chronically ventilated
premature infants. Pediatr Res 2004;56(6):918–926. [PubMed: 15496605]
9. Laughon M, Bose C, Allred E, et al. Factors associated with treatment for hypotension in extremely
low gestational age newborns during the first postnatal week. Pediatrics 2007;119(2):273–280.
[PubMed: 17272616]
Laughon et al. Page 7













10. Hecht J, Onderdonk A, Delaney M, et al. Characterization of chorioamnionitis in second trimester c-
section placentas and correlation with microorganism recovery from sub-amniotic tissues. Pediatr
Dev Pathol 2007;11(1):15–22. [PubMed: 18237241]
11. Hecht JL, Kliman HJ, Allred EN, et al. Reference weights for placentas delivered before the 28th
week of gestation. Placenta 2007;28(10):987–990. [PubMed: 17573110]
12. Hecht JL, Onderdonk A, Delaney M, et al. Characterization of chorioamnionitis in 2nd-trimester c-
section placentas and correlation with microorganism recovery from subamniotic tissues. Pediatr
Dev Pathol 2008;11(1):15–22. [PubMed: 18237241]
13. Onderdonk AB, Delaney ML, DuBois AM, Allred EN, Leviton A. Detection of bacteria in placental
tissues obtained from extremely low gestational age neonates. Am J Obstet Gynecol 2008;198(1):
110,e1–e7. [PubMed: 18166321]
14. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: simplified newborn
illness severity and mortality risk scores. J Pediatr 2001;138(1):92–100. [PubMed: 11148519]
15. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the
epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995;126(4):605–610.
[PubMed: 7699543]
16. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O'Shea TM. Risk factors for chronic
lung disease in the surfactant era: a North Carolina population-based study of very low birth weight
infants. North Carolina Neonatologists Association. Pediatrics 1999;104(6):1345–1350. [PubMed:
10585987]
17. Beresford MW, Shaw NJ. Detectable IL-8 and IL-10 in bronchoalveolar lavage fluid from preterm
infants ventilated for respiratory distress syndrome. Pediatr Res 2002;52(6):973–978. [PubMed:
12438678]
18. Leviton A, Blair E, Dammann O, Allred E. The wealth of information conveyed by gestational age.
J Pediatr 2005;146(1):123–127. [PubMed: 15644836]
19. Watterberg KL. Adrenocortical function and dysfunction in the fetus and neonate. Semin Neonatol
2004;9(1):13–21. [PubMed: 15013472]
20. Goldenberg RL, Andrews WW, Faye-Petersen OM, Goepfert AR, Cliver SP, Hauth JC. The Alabama
Preterm Birth Study: intrauterine infection and placental histologic findings in preterm births of males
and females less than 32 weeks. Am J Obstet Gynecol 2006;195(6):1533–1537. [PubMed: 16796981]
21. Kallapur SG, Jobe AH. Contribution of inflammation to lung injury and development. Arch Dis Child
Fetal Neonatal Ed 2006;91(2):F132–F135. [PubMed: 16492951]
22. Van Marter LJ, Dammann O, Allred EN, et al. Chorioamnionitis, mechanical ventilation, and
postnatal sepsis as modulators of chronic lung disease in preterm infants. J Pediatr 2002;140(2):171–
176. [PubMed: 11865267]
23. Kotecha S, Hodge R, Schaber JA, Miralles R, Silverman M, Grant WD. Pulmonary Ureaplasma
urealyticum is associated with the development of acute lung inflammation and chronic lung disease
in preterm infants. Pediatr Res 2004;55(1):61–68. [PubMed: 14605250]
24. Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate
treatment strategies. J Pediatr 1996;128(5 pt 1):601–607. [PubMed: 8627430]
25. Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-
analysis. Arch Dis Child Fetal Neonatal Ed 2003;88(6):F464–F466. [PubMed: 14602691]
Abbreviations
PD pulmonary deterioration
ELGAN extremely low gestational age newborn
CLD chronic lung disease
PDA patent ductus arteriosus
EPPD early and persistent pulmonary dysfunction
FIO2 fraction of inspired oxygen
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SNAP-II Score for Neonatal Acute Physiology II
RDS respiratory distress syndrome
BPD bronchopulmonary dysplasia
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Median of the mode FIO2 on postnatal days 0 to 7 and on postnatal day 14 and frequency of
CLD among 1340 ELGANs with 3 patterns of respiratory disease (low FIO2, PD, and EPPD)
during the first 2 postnatal weeks.
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Incidence of mechanical ventilation (conventional or high frequency) by postnatal days 0 to 7
and by group (low FIO2, PD, and EPPD).
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TABLE 4
Multivariate Analysis of ELGANs in the PD Group Versus the Low FIO2 Group
Characteristic Odds Ratio (95% Confidence Interval) P
Gestational age, wk
 23 2.5 (0.5–12) .25
 24 3.6 (1.8–7.3) ≤.0005
 25 2.4 (1.4–4.0) .001
 26 1.5 (1.0–2.3) .04
 27 1.0
Birth weight z score
 Less than −1 2.8 (1.7–4.9) ≤.0005
 −1 to 0 1.7 (1.2–2.5) .003
 ≥0 1.0
Mechanical ventilation, conventional or high frequency, on postnatal day 7 3.2 (2.4–4.8) ≤.0005
PDA diagnosis 1.4 (0.98–2.0) .07
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TABLE 5
Multivariate Analysis of ELGANs in the EPPD Group Versus the Low FIO2 Group
Characteristic Odds Ratio (95% Confidence Interval) P
Gestational age, wk
 23 13 (2.7–59) .001
 24 4.2 (2.0–9.1) ≤.0005
 25 3.8 (2.1–6.9) ≤.0005
 26 2.8 (1.7–4.6) ≤.0005
 27 1.0
Birth weight z score
 Less than −1 3.1 (1.7–5.7) ≤.0005
 −1 to 0 1.6 (1.0–2.6) .04
 ≥0 1.0
Mechanical ventilation, conventional or high frequency, on postnatal day 7 9.5 (6.1–15) ≤.0005
PDA diagnosis 1.4 (0.98–2.0) .06
Confirmed bacteremia 1.7 (1.1–2.6) .02
Hydrocortisone 2.4 (0.9–6.5) .10
Vitamin A 1.8 (1.1–3.0) .02
Surfactant 4.6 (2.2–9.5) ≤.0005
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